D
David Dolling
Researcher at Institute of Cancer Research
Publications - 49
Citations - 4341
David Dolling is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Prostate cancer & Cancer biomarkers. The author has an hindex of 22, co-authored 48 publications receiving 3038 citations. Previous affiliations of David Dolling include Medical Research Council & The Royal Marsden NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.
Sheena McCormack,David Dunn,Monica Desai,David Dolling,Mitzy Gafos,Richard Gilson,Richard Gilson,Ann Sullivan,Amanda Clarke,Iain Reeves,Gabriel Schembri,Nicola Mackie,Christine Bowman,Charles J.N. Lacey,Vanessa Apea,Michael Brady,Julie Fox,Stephen Taylor,Simone Antonucci,Saye Khoo,James F. Rooney,Anthony Nardone,Martin Fisher,Alan McOwan,Andrew N. Phillips,Anne M Johnson,Brian Gazzard,ON Gill +27 more
TL;DR: In this high incidence population, daily tenofovir–emtricitabine conferred even higher protection against HIV than in placebo-controlled trials, refuting concerns that effectiveness would be less in a real-world setting.
Journal ArticleDOI
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
Jane Goodall,Joaquin Mateo,Joaquin Mateo,Wei Yuan,Helen Mossop,Nuria Porta,Susana Miranda,Raquel Perez-Lopez,Raquel Perez-Lopez,David Dolling,Dan R. Robinson,Shahneen Sandhu,Gemma Fowler,Berni Ebbs,Penny Flohr,George Seed,Daniel Nava Rodrigues,Daniel Nava Rodrigues,Gunther Boysen,Claudia Bertan,Mark Atkin,Matthew Clarke,Mateus Crespo,Ines Figueiredo,Ruth Riisnaes,Semini Sumanasuriya,Semini Sumanasuriya,Pasquale Rescigno,Pasquale Rescigno,Zafeiris Zafeiriou,Zafeiris Zafeiriou,Adam Sharp,Adam Sharp,Nina Tunariu,Nina Tunariu,Diletta Bianchini,Diletta Bianchini,Alexa Gillman,Christopher J. Lord,Emma Hall,Arul M. Chinnaiyan,Suzanne Carreira,Johann S. de Bono,Johann S. de Bono +43 more
TL;DR: Target and whole-exome sequencing of serial circulating cell-free DNA samples collected during a phase II trial of olaparib provide predictive, prognostic, response, and resistance data with "second hit" mutations first detectable at disease progression, suggesting clonal evolution from treatment-selective pressure and platinum resistance.
Journal ArticleDOI
Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.
Alison Birtle,Alison Birtle,Mark Johnson,John D. Chester,Robert Jones,David Dolling,Richard T. Bryan,Chris Harris,Andrew Winterbottom,Anthony Blacker,James W.F. Catto,Prabir Chakraborti,Jenny L Donovan,Paul Anthony Elliott,Ann French,Satinder Jagdev,Benjamin Jenkins,Francis X. Keeley,Roger Kockelbergh,Thomas Powles,John Wagstaff,Caroline Wilson,Rachel Todd,Rebecca Lewis,Emma Hall +24 more
TL;DR: Gemcitabine–platinum combination chemotherapy initiated within 90 days after nephroureterectomy significantly improved disease-free survival in patients with locally advanced UTUC in a phase 3, open-label, randomised controlled trial.
Journal ArticleDOI
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
Arianna Calcinotto,Clarissa Spataro,Elena Zagato,Diletta Di Mitri,Veronica Gil,Mateus Crespo,Gaston De Bernardis,Marco Losa,Michela Mirenda,Emiliano Pasquini,Andrea Rinaldi,Semini Sumanasuriya,Maryou B. Lambros,Antje Neeb,Roberta Lucianò,Carlo Andrea Bravi,Daniel Nava-Rodrigues,David Dolling,Tommaso Prayer-Galetti,Ana Ferreira,Alberto Briganti,Antonio Esposito,Simon T. Barry,Wei Yuan,Adam Sharp,Johann S. de Bono,Andrea Alimonti +26 more
TL;DR: Results reveal that MDSCs promote CRPC by acting in a non-cell autonomous manner and Treatments that block IL-23 can oppose MDSC-mediated resistance to castration in prostate cancer and synergize with standard therapies.
Journal ArticleDOI
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
Adam Sharp,Adam Sharp,Ilsa Coleman,Wei Yuan,Cynthia C. Sprenger,David Dolling,Daniel Nava Rodrigues,Joshua W. Russo,Ines Figueiredo,Claudia Bertan,George Seed,Ruth Riisnaes,Takuma Uo,Antje Neeb,Jonathan Welti,Colm Morrissey,Suzanne Carreira,Jun Luo,Peter S. Nelson,Peter S. Nelson,Steven P. Balk,Lawrence D. True,Johann S. de Bono,Johann S. de Bono,Stephen R. Plymate +24 more
TL;DR: It is demonstrated that AR-V7 protein is rarely expressed in primary PC but is frequently detected following androgen deprivation therapy, with further significant increase in expression following abiraterone acetate or enzalutamide therapy, which provides impetus to develop therapies that abrogate AR-v7 signaling.